Literature DB >> 14563098

Assessment and treatment of hot flushes and menopausal mood disturbance.

Hadine Joffe1, Claudio N Soares, Lee S Cohen.   

Abstract

More than 1 million women are expected to reach menopause each year, many of whom will experience hot flushes and other neuropsychological symptoms that may diminish their quality of life. Hot flushes are the core symptoms that reflect the brain's response to the changing hormonal milieu of the menopause transition, particularly to the rapidly fluctuating and falling levels of estradiol. The physical symptoms of hot flushes and the associated changes in sleep, mood, and cognition will lead many women to seek medical care. It is critical to understand the interrelationship of hot flushes and other neuropsychological symptoms of the menopause transition so that treatment priorities can be established. For example, if sleep disruption explains most daytime neuropsychological problems in women with hot flushes, treating insomnia should be considered a priority. Alternatively, mood, cognition, and quality of life may be disturbed independent of sleep problems. In such a situation, each symptom should be evaluated separately from any assessment of sleep. As recent data from the WHI establish the risks of long-term HRT use, concern about using HRT, even as a short-term intervention, has increased substantially. Although HRT remains the first-line treatment for hot flushes, the WHI findings have drawn attention to nonhormonal treatments of hot flushes and other menopausal symptoms. Growing evidence to support the efficacy of serotonergic antidepressants and other psychoactive medications in the treatment for hot flushes suggests that nonhormonal interventions will prove important alternatives to HRT. As further evidence of the benefits of psychoactive medications for menopausal symptoms is established, the choice between using hormonal and nonhormonal therapies for management of menopausal symptoms will continue to evolve.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14563098     DOI: 10.1016/s0193-953x(03)00045-5

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN: 0193-953X


  10 in total

1.  Progesterone's effects to reduce anxiety behavior of aged mice do not require actions via intracellular progestin receptors.

Authors:  C A Frye; K Sumida; B C Dudek; J P Harney; J P Lydon; B W O'Malley; D W Pfaff; M E Rhodes
Journal:  Psychopharmacology (Berl)       Date:  2006-03-15       Impact factor: 4.530

2.  Progesterone reduces depressive behavior of young ovariectomized, aged progestin receptor knockout, and aged wild type mice in the tail suspension test.

Authors:  Cheryl A Frye
Journal:  J Psychopharmacol       Date:  2009-12-04       Impact factor: 4.153

3.  Effects of pharmacologically induced hypogonadism on mood and behavior in healthy young women.

Authors:  Rivka Ben Dor; Veronica L Harsh; Paige Fortinsky; Deloris E Koziol; David R Rubinow; Peter J Schmidt
Journal:  Am J Psychiatry       Date:  2013-04       Impact factor: 18.112

4.  The effect of folic Acid on menopausal hot flashes: a randomized clinical trial.

Authors:  Soheila Bani; Shirin Hasanpour; Leila Farzad Rik; Hadi Hasankhani; Seiedeh Hajar Sharami
Journal:  J Caring Sci       Date:  2013-06-01

5.  Mindfulness training for coping with hot flashes: results of a randomized trial.

Authors:  James Francis Carmody; Sybil Crawford; Elena Salmoirago-Blotcher; Katherine Leung; Linda Churchill; Nicholas Olendzki
Journal:  Menopause       Date:  2011-06       Impact factor: 2.953

Review 6.  Mind-body therapies for menopausal symptoms: a systematic review.

Authors:  Kim E Innes; Terry Kit Selfe; Abhishek Vishnu
Journal:  Maturitas       Date:  2010-02-18       Impact factor: 4.342

Review 7.  Menopause, the metabolic syndrome, and mind-body therapies.

Authors:  Kim E Innes; Terry Kit Selfe; Ann Gill Taylor
Journal:  Menopause       Date:  2008 Sep-Oct       Impact factor: 2.953

8.  Effectiveness of yoga for menopausal symptoms: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Holger Cramer; Romy Lauche; Jost Langhorst; Gustav Dobos
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-07       Impact factor: 2.629

9.  Dose-Dependent Effects of the Cimicifuga racemosa Extract Ze 450 in the Treatment of Climacteric Complaints: A Randomized, Placebo-Controlled Study.

Authors:  Ruediger Schellenberg; Reinhard Saller; Lorenzo Hess; Jörg Melzer; Christian Zimmermann; Juergen Drewe; Catherine Zahner
Journal:  Evid Based Complement Alternat Med       Date:  2012-12-23       Impact factor: 2.629

10.  Prediction of risk of depressive symptoms in menopausal women based on hot flash and sweating symptoms: a multicentre study.

Authors:  Yanwei Zheng; Yibei Zhou; Jiangshan Hu; Jieping Zhu; Qi Hua; Minfang Tao
Journal:  Clin Interv Aging       Date:  2017-11-23       Impact factor: 4.458

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.